Skip to main content

Involutional Osteoporosis

6
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
5
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Ono Pharmaceutical
Ono PharmaceuticalJapan - Osaka
3 programs
3
Minodronic acid hydratePhase 31 trial
ONO-5920Phase 31 trial
ONO-5920Phase 31 trial
Active Trials
NCT00212628Completed444
NCT00212667Completed650
NCT00212719Completed250
Astellas
AstellasChina - Shenyang
2 programs
2
Minodronic acid hydratePhase 3
ONO-5920Phase 3
EA Pharma
EA PharmaJapan - Tokyo
1 program
1
NE-58095 IRPhase 2/31 trial
Active Trials
NCT02063854Completed871Est. Nov 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ono PharmaceuticalMinodronic acid hydrate
Ono PharmaceuticalONO-5920
Ono PharmaceuticalONO-5920
EA PharmaNE-58095 IR

Clinical Trials (4)

Total enrollment: 2,215 patients across 4 trials

NCT00212628Ono PharmaceuticalMinodronic acid hydrate

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Start: Jun 2004444 patients
Phase 3Completed
NCT00212719Ono PharmaceuticalONO-5920

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Start: May 2003250 patients
Phase 3Completed
NCT00212667Ono PharmaceuticalONO-5920

Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan

Start: Aug 2002650 patients
Phase 3Completed
NCT02063854EA PharmaNE-58095 IR

A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets

Start: Feb 2014Est. completion: Nov 2015871 patients
Phase 2/3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 late-stage (Phase 3) programs, potential near-term approvals
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.